Search results for "Intensive Care Medicine"

showing 10 items of 2228 documents

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease

2018

Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and …

0301 basic medicinemedicine.medical_specialtyConsensusDelphi study; Gaucher disease; Management goals; PROMs; TherapyDelphi methodEarly detectionGaucher diseaseDiseasePROMs03 medical and health sciences0302 clinical medicineQuality of life (healthcare)HumansMedicineIntensive care medicineSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSManagement goalsbusiness.industryDisease ManagementType 1 Gaucher DiseaseExpert consensus[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologySocial engagementDelphi study3. Good healthEurope030104 developmental biology030220 oncology & carcinogenesisQuality of LifePhysical therapyMolecular MedicineTherapybusinessBlood Cells, Molecules, and Diseases
researchProduct

Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region

2019

Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low …

0301 basic medicinemedicine.medical_specialtyConsensusEndocrinology Diabetes and MetabolismOsteoporosis030209 endocrinology & metabolismBone resorption makerAsia pacific regionCollagen Type IBone remodeling03 medical and health sciences0302 clinical medicineN-terminal telopeptideBone DensityOsteoporosis treatmentHealth caremedicineHumansRadiology Nuclear Medicine and imagingOrthopedics and Sports MedicineIntensive care medicineReimbursementAnabolicsBone mineralddc:616Hip Fracturesbusiness.industryAnti-resorptivesmedicine.diseasePeptide FragmentsBone formation makerOsteoporosisBone Remodeling030101 anatomy & morphologybusinessBiomarkersProcollagen
researchProduct

The role of immunogenetics in covid‐19

2021

Coronavirus disease 2019 (COVID-19) is induced by SARS-CoV-2 and may arise as a variety of clinical manifestations, ranging from an asymptomatic condition to a life-threatening disease associated with cytokine storm, multiorgan and respiratory failure. The molecular mechanism behind such variability is still under investigation. Several pieces of experimental evidence suggest that genetic variants influencing the onset, maintenance and resolution of the immune response may be fundamental in predicting the evolution of the disease. The identification of genetic variants behind immune system reactivity and function in COVID-19 may help in the elaboration of personalized therapeutic strategies…

0301 basic medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ReviewDiseaseImmunogeneticsHuman leukocyte antigenSeverity of Illness IndexCatalysisSARS‐CoV‐2ABO Blood-Group SystemInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineCOVID‐19HLA AntigensmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseGenetic variabilityPhysical and Theoretical ChemistryIntensive care medicineMolecular Biologylcsh:QH301-705.5SpectroscopyAB0business.industrySARS-CoV-2Organic ChemistryImmunityCOVID-19General MedicineImmunosenescencemedicine.disease3. Good healthComputer Science ApplicationsKIRHLA030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisIdentification (biology)Disease SusceptibilityCytokine stormbusiness
researchProduct

Development of artemisinin resistance in malaria therapy

2019

Malaria affects 200 million people worldwide. Today, the most successful treatments are artemisinin-based combination therapies (ACT). Resistance has already been described for the elder anti-malarials chloroquine, sulfadoxine-pyrimethamine and mefloquine. Unfortunately, over the last few years there has also been an emerging resistance to the successfully used drug artemisinin, especially in African and Asian countries. A systematic PubMed literature research was conducted for studies published between January 2002 and December 2018. Despite ACTs continue to be first line treatment, the number of studies is rising reporting on artemisinin resistance mutations. Most publications reported on…

0301 basic medicinemedicine.medical_specialtyDrug ResistanceAntimalarials03 medical and health sciences0302 clinical medicineChloroquineparasitic diseasesAsian countryAnimalsHumansMedicineArtemisininIntensive care medicinePharmacologyPolymorphism Geneticbusiness.industryMefloquineArtemisinin resistancemedicine.diseaseArtemisininsTreatment efficacyMalariaFirst line treatment030104 developmental biology030220 oncology & carcinogenesisMutationbusinessMalariamedicine.drugPharmacological Research
researchProduct

Should we administer antifungal drugs before the diagnosis of invasive fungal infection in non-neutropenic critically ill patients?

2016

0301 basic medicinemedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain MedicineCritically illbusiness.industryAntifungal drugsAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE First Round030106 microbiologysepsis fungal infectionNon neutropenic03 medical and health sciencesAnesthesiology and Pain Medicine0302 clinical medicineEmergency Medicinemedicine030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness
researchProduct

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures

2019

Summary Guidance is provided in an international setting on the assessment and specific treatment of postmenopausal women at low, high and very high risk of fragility fractures. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2019. This manuscript seeks to apply this in an international setting, taking additional account of further categorisation of increased risk of fracture, which may inform choice of therapeutic approach. Methods Clinical perspective and updated literature search. Results The following areas are reviewed: …

0301 basic medicinemedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismeducationOsteoporosisPsychological interventioninhibitors of bone resorption030209 endocrinology & metabolismRisk AssessmentAnabolic agents03 medical and health sciencesTherapeutic approach0302 clinical medicineBone DensityRisk FactorsTreatment of osteoporosisInternal medicinemedicinefracture risk assessmentHumansanabolic agentsIntensive care medicineOsteoporosis PostmenopausalAgedAnabolic agents Fracture risk assessment FRAX Inhibitors of bone resorption Treatment of osteoporosisddc:616Postmenopausal womenbusiness.industryCorrectionFracture risk assessmentInhibitors of bone resorptionMiddle Agedtreatment of osteoporosismedicine.diseaseRheumatologyIncreased riskFemalePosition Paper030101 anatomy & morphologybusinessVery high riskAlgorithmsOsteoporotic FracturesFRAXOsteoporosis International
researchProduct

An "aubergine" in the heart: huge native mitral valve endocarditis caused by Streptococcus agalactiae.

2017

0301 basic medicinemedicine.medical_specialtyFever030106 microbiologyMEDLINE030204 cardiovascular system & hematologymedicine.disease_causeStreptococcus agalactiae03 medical and health sciencesMitral valve endocarditis0302 clinical medicineStreptococcal InfectionsInternal MedicinemedicineHumansIntensive care medicineEndocarditisbusiness.industryMiddle AgedDyspneaStreptococcus agalactiaeItalyEchocardiographyEmergency MedicineChordae TendineaeMitral ValveFemalebusinessEmergency Service HospitalInternal and emergency medicine
researchProduct

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome

2018

Abstract Aim Mucopolysaccharidosis type I is a lysosomal storage disorder that can result in significant disease burden, disability and premature death, if left untreated. The aim of this review was to elaborate on the diagnosis of mucopolysaccharidosis type I and the pros and cons of newborn screening. Methods An international working group was established to discuss ways to improve the early diagnosis of mucopolysaccharidosis type I. It consisted of 13 experts in paediatrics, rare diseases and inherited metabolic diseases from Europe and the Middle East. Results It is becoming increasingly clearer that the delay between symptom onset and clinical diagnosis is considerable for mucopolysacc…

0301 basic medicinemedicine.medical_specialtyHaematopoietic stem cell transplantLysosomal storage disorderMucopolysaccharidosis ILysosomal storage disordersReview ArticleDisease03 medical and health sciencesMucopolysaccharidosis type INeonatal Screening0302 clinical medicinemedicineHumansLaronidasePediatrics Perinatology and Child HealthIntensive care medicineReview ArticlesDisease burdenNewborn screeningbusiness.industryMucopolysaccharidosis type IInfant NewbornGeneral MedicineEnzyme replacement therapyInternational working group030104 developmental biologyEnzyme replacement therapyClinical diagnosisPediatrics Perinatology and Child Healthbusiness030217 neurology & neurosurgeryActa Paediatrica
researchProduct

What Healthcare Workers Should Know about Environmental Bacterial Contamination in the Intensive Care Unit

2017

Intensive care unit- (ICU-) acquired infections are a major health problem worldwide. Inanimate surfaces and equipment contamination may play a role in cross-transmission of pathogens and subsequent patient colonization or infection. Bacteria contaminate inanimate surfaces and equipment of the patient zone and healthcare area, generating a reservoir of potential pathogens, including multidrug resistant species. Traditional terminal cleaning methods have limitations. Indeed patients who receive a bed from prior patient carrying bacteria are exposed to an increased risk (odds ratio 2.13, 95% confidence intervals 1.62–2.81) of being colonized and potentially infected by the same bacterial spec…

0301 basic medicinemedicine.medical_specialtyHealth Personnel030106 microbiologylcsh:MedicineReview ArticleGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health scienceslawLong periodHealth caremedicineHumansInfection controlTerminal cleaningMED/41 - ANESTESIOLOGIAIntensive care medicineDecontaminationCross InfectionInfection ControlHealthcare Environmental Bacterial Contamination Intensive Care Unit.General Immunology and Microbiologybusiness.industrylcsh:RGeneral MedicineContaminationIntensive care unitIntensive Care UnitsIncreased riskEquipment ContaminationEquipment ContaminationEnvironmental PollutionbusinessHumanBioMed Research International
researchProduct